iBio vs Cartesian Therapeutics
IBIO and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IBIO and RNAC compare
Cartesian Therapeutics is the larger company, worth 4.1 times as much as iBio ($192M against $47.1M).
iBio keeps more of each dollar of sales as profit, with a net margin of −3244% compared with −12435% at Cartesian Therapeutics.
iBio scores higher on the StockData Score (9 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IBIO | RNAC |
|---|---|---|
| Size and price | ||
| Market cap | $47.1M | $192M |
| Share price | $0.732 | $6.36 |
| Change, 1 year | −41.5% | −12.9% |
| Change, 5 years | −99.8% | −93.4% |
| Beta (5Y) | 1.12 | 1.39 |
| Employees | 23 | 75 |
| StockData Score | ||
| Total score | 9 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 43.8× (better) | 188× |
| P/B | 0.6× | – |
| FCF yield | −58.6% | −46.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 115% | – |
| Revenue growth, 5Y average | −46.9% | −30.0% (better) |
| Profitability | ||
| Operating margin | −3491% (better) | −15541% |
| Net margin | −3244% (better) | −12435% |
| FCF margin | −2566% (better) | −8770% |
| Return on equity | −51.8% | – |
| Return on invested capital | −728% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 9.48 (better) | 8.38 |
| Altman Z-score | −3.49 (better) | −5.12 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 54.0% | 29.3% |
| Held by insiders | 0.47% | 55.7% |
| Insider net buying, 12 months | $98.1K (better) | −$52.9K |
| Short interest, % of float | 6.3% | 14.3% |
Go deeper
- IBIO stock overview
- IBIO income statement
- IBIO valuation and score
- RNAC stock overview
- RNAC income statement
- RNAC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.